{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild-Moderate+Alzheimer%27s+Disease&page=6",
    "query": {
      "condition": "Mild-Moderate Alzheimer's Disease",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 205,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild-Moderate+Alzheimer%27s+Disease&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild-Moderate+Alzheimer%27s+Disease&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T05:39:06.242Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01504854",
      "title": "Resveratrol for Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Resveratrol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alzheimer's Disease Cooperative Study (ADCS)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2012-05",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2016-06-14",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01504854"
    },
    {
      "nct_id": "NCT01369225",
      "title": "Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "AAB-003 (PF-05236812)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-07",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 15,
      "location_summary": "Hallandale, Florida • Ocala, Florida • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369225"
    },
    {
      "nct_id": "NCT02256306",
      "title": "The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild-To-Moderate Alzheimer's Disease",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Plasma",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 18,
      "start_date": "2014-09",
      "completion_date": "2017-02",
      "has_results": false,
      "last_update_posted_date": "2017-10-10",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02256306"
    },
    {
      "nct_id": "NCT00550420",
      "title": "Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": "91 Years",
        "sex": "ALL",
        "summary": "51 Years to 91 Years"
      },
      "enrollment_count": 331,
      "start_date": "2007-10-01",
      "completion_date": "2009-02-12",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 9,
      "location_summary": "Palo Alto, California • Deerfield Beach, Florida • Hialeah, Florida + 6 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00550420"
    },
    {
      "nct_id": "NCT03316898",
      "title": "A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "AGN-242071",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Memantine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-09-30",
      "completion_date": "2018-11-04",
      "has_results": false,
      "last_update_posted_date": "2018-11-02",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 6,
      "location_summary": "Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316898"
    },
    {
      "nct_id": "NCT03019536",
      "title": "A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "LY3303560 - IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo - IV",
          "type": "DRUG"
        },
        {
          "name": "Florbetapir F 18",
          "type": "DRUG"
        },
        {
          "name": "Flortaucipir F18",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-01-31",
      "completion_date": "2019-06-05",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 5,
      "location_summary": "Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more",
      "locations": [
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03019536"
    },
    {
      "nct_id": "NCT00667810",
      "title": "Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "bapineuzumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 901,
      "start_date": "2008-06",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2016-01-08",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 164,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667810"
    },
    {
      "nct_id": "NCT00103649",
      "title": "18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "xaliproden (SR57746A)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1306,
      "start_date": "2003-11",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2008-08-21",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 97,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103649"
    },
    {
      "nct_id": "NCT05194163",
      "title": "MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "MW150",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurokine Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-05-01",
      "completion_date": "2024-11-30",
      "has_results": false,
      "last_update_posted_date": "2022-03-29",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194163"
    },
    {
      "nct_id": "NCT00348309",
      "title": "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone Extended Release 2mg",
          "type": "DRUG"
        },
        {
          "name": "Rosiglitazone Extended Release 8mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Donepezil",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 1496,
      "start_date": "2006-07-06",
      "completion_date": "2009-01-28",
      "has_results": true,
      "last_update_posted_date": "2017-11-28",
      "last_synced_at": "2026-11-20T05:39:06.242Z",
      "location_count": 41,
      "location_summary": "Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more",
      "locations": [
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00348309"
    }
  ]
}